Related Experiment Video
Updated: Mar 7, 2026
09:02
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
12.5K
Carfilzomib boosted combination therapy for relapsed multiple myeloma
Raphael E Steiner1, Elisabet E Manasanch1
1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oncotargets and Therapy
|March 1, 2017
Summary
Carfilzomib, a proteasome inhibitor, effectively treats relapsed multiple myeloma. Combination therapies with carfilzomib show promising efficacy, safety, and quality of life improvements for patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Carfilzomib is an irreversible proteasome inhibitor targeting the 20S proteasome.
- It induces tumor cell apoptosis and growth arrest, improving outcomes in multiple myeloma.
Purpose of the Study:
- To review the efficacy, safety, tolerability, and quality of life of carfilzomib-based combination therapies.
- To discuss novel agents used in combination with carfilzomib for relapsed multiple myeloma.
Main Methods:
- Literature review of clinical studies and trials involving carfilzomib.
- Analysis of data on carfilzomib in monotherapy and combination regimens.
Main Results:
- Carfilzomib is approved for relapsed/refractory multiple myeloma and used in early relapse settings.
- Combinations with lenalidomide, dexamethasone, and other agents are under investigation.
Conclusions:
- Carfilzomib-based therapies represent a significant advancement in multiple myeloma treatment.
- Further research is ongoing to optimize combination strategies and novel agent integration.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
670
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
670
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
584
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
584
01:28Drug Therapy
346
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
346